Jeron Selvain Publishes SCI-Level Paper on Intractable Disease Treatment Using Self-Developed PDRN-Based Drug

Polideoxyribonucleotide (PRDN)-based specialty pharmaceutical company Jeron Selvain announced on the 1st that its research paper on an intractable disease treatment under development was published in the SCI-level international journal, International Journal of Biological Macromolecules.

Jeron Selvain has been conducting research on the topic of "Multifunctional Alginate/PDRN Hydrogel for Promoting Diabetic Wound Healing." This treatment is an intractable disease therapy primarily indicated for difficult-to-treat conditions such as diabetic foot ulcers.

Typically, diabetic wound diseases are known to heal slowly even from small wounds, and in severe cases, ulcers worsen to the point where amputation of the affected area may be necessary. In the case of diabetic foot, there are currently no effective treatments, resulting in many cases of leg amputation due to skin necrosis.

Accordingly, Jeron Selvain has been developing a hydrogel-based wound treatment incorporating PRDN, a tissue regeneration-promoting substance, to enhance drug efficacy and improve patient convenience.

PRDN is a DNA substance extracted from salmon germ cells. It is similar to human DNA, causing fewer side effects, and induces self-regeneration of damaged cells and cell growth. Additionally, hydrogels have a structure similar to the extracellular matrix that composes biological tissues, providing excellent biocompatibility.

Jeron Selvain has already partially confirmed the efficacy of the drug through experiments using a diabetic mouse model. According to the company, Jeron Selvain’s multifunctional alginate/PDRN hydrogel showed significantly faster wound closure rates in experiments compared to hydrogels without PDRN.

Kim Deok-gyu, CEO of Jeron Selvain, stated, “The multifunctional alginate/PDRN hydrogel has tremendous therapeutic potential as a diabetic wound dressing,” and added, “The publication of this paper suggests that this treatment can provide better care to patients as a new therapeutic model.”

He continued, “We will continue to devote our efforts to research and development so that the multifunctional alginate/PDRN hydrogel can establish itself as a promising diabetic wound treatment,” and added, “We plan to develop it further for application in various products such as ointments and moist bandages.”